VIP152

DRUG2 trials

Sponsors

Vincerx Pharma, Inc., National Cancer Institute (NCI)

Conditions

Chronic Lymphocytic LeukemiaHematologic MalignanciesLymphoid MalignanciesLymphomaMYC AmplificationMYC OverexpressionMYC TranslocationNHL

Phase 1

A Study to Evaluate VIP152 in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia or Richter Syndrome

TerminatedNCT04978779

Vincerx Pharma, Inc.Chronic Lymphocytic Leukemia, MYC Amplification, MYC Overexpression +4

Start: 2021-12-16End: 2023-05-26Updated: 2023-11-18

Study of VIP152, Venetoclax, and Prednisone (VVIP) in Relapsed/Refractory Lymphoid Malignancies

CompletedNCT05371054

National Cancer Institute (NCI)Hematologic Malignancies, Lymphoid Malignancies, Lymphoma +2

Start: 2023-04-05End: 2025-12-16Updated: 2026-02-23

Related Papers

Abstract 1859: VIP152, a selective CDK9 inhibitor, demonstrates sensitivity in gynecologic cell lines that are cisplatin sensitive or resistant and delivers <i>in vivo</i> antitumor efficacy

Cancer Research2022-06-152 citations

P1269: VIP152 IS A NOVEL CDK9 INHIBITOR WITH IMPROVED SELECTIVITY, TARGET MODULATION, AND CARDIAC SAFETY IN PATIENTS WITH LYMPHOMA

HemaSphere2022-06-012 citations

VIP152 Is a Novel CDK9 Inhibitor with Efficacy in Chronic Lymphocytic Leukemia

Blood2021-11-053 citations

VIP152, a Selective CDK9 Inhibitor, Induces Complete Regression in a High-Grade B-Cell Lymphoma (HGBL) Model and Depletion of Short-Lived Oncogenic Driver Transcripts, MYC and MCL1, with a Once Weekly Schedule

Blood2021-11-052 citations